Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

BACKGROUND: Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occ...

Descripción completa

Detalles Bibliográficos
Autores principales: Follmann, Dean, Fintzi, Jonathan, Fay, Michael P., Janes, Holly E., Baden, Lindsey, Sahly, Hana El, Fleming, Thomas R., Mehrotra, Devan V., Carpp, Lindsay N., Juraska, Michal, Benkeser, David, Donnell, Deborah, Fong, Youyi, Han, Shu, Hirsch, Ian, Huang, Ying, Huang, Yunda, Hyrien, Ollivier, Luedtke, Alex, Carone, Marco, Nason, Martha, Vandebosch, An, Zhou, Honghong, Cho, Iksung, Gabriel, Erin, Kublin, James G., Cohen, Myron S., Corey, Lawrence, Gilbert, Peter B., Neuzil, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745130/
https://www.ncbi.nlm.nih.gov/pubmed/33336213
http://dx.doi.org/10.1101/2020.12.14.20248137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745130/
https://www.ncbi.nlm.nih.gov/pubmed/33336213
http://dx.doi.org/10.1101/2020.12.14.20248137

Ejemplares similares